BridgeBio Pharma (BBIO) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for BridgeBio Pharma (BBIO) over the last 6 years, with Q3 2025 value amounting to -$0.95.
- BridgeBio Pharma's EPS (Weighted Average and Diluted) fell 1046.51% to -$0.95 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.2, marking a year-over-year decrease of 7427.39%. This contributed to the annual value of -$2.88 for FY2024, which is 2710.72% up from last year.
- Latest data reveals that BridgeBio Pharma reported EPS (Weighted Average and Diluted) of -$0.95 as of Q3 2025, which was down 1046.51% from -$0.95 recorded in Q2 2025.
- BridgeBio Pharma's 5-year EPS (Weighted Average and Diluted) high stood at -$0.07 for Q2 2022, and its period low was -$1.42 during Q4 2024.
- Over the past 5 years, BridgeBio Pharma's median EPS (Weighted Average and Diluted) value was -$0.94 (recorded in 2022), while the average stood at -$0.87.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first soared by 8939.39% in 2022, then plummeted by 130000.0% in 2023.
- Over the past 5 years, BridgeBio Pharma's EPS (Weighted Average and Diluted) (Quarter) stood at -$1.02 in 2021, then increased by 9.76% to -$0.92 in 2022, then decreased by 4.35% to -$0.96 in 2023, then plummeted by 48.38% to -$1.42 in 2024, then surged by 33.31% to -$0.95 in 2025.
- Its last three reported values are -$0.95 in Q3 2025, -$0.95 for Q2 2025, and -$0.88 during Q1 2025.